Ken Griffin
PMN icon

Ken Griffin’s ProMIS Neurosciences PMN Stock Holding History

Ken Griffin’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,803
Closed -$72.3K – 13750
2025
Q3 		$72.3K Buy
6,803
+4,266
+168% +$59.1K ﹤0.01% 12018
2025
Q2 		$31.1K Buy
+2,537
New +$34.6K ﹤0.01% 11970

Other funds holding PMN

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
DEM
Disciplined Equity Management Neptune Beach, Florida $226M AUM 27.21% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ken Griffin's PMN Position: Q4 2025 in Review

Ken Griffin sold out of ProMIS Neurosciences (PMN) in Q4 2025, closing a stake of 6,803 shares — an estimated $72.3K sold.

Ken Griffin first reported a position in PMN in Q2 2025 and held it in 2 quarters. The position peaked at $72.3K in Q3 2025. 9 funds tracked by Wall St. Rank hold PMN as of Q4 2025.

  • Ken Griffin reported no remaining ProMIS Neurosciences position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 6,803 ProMIS Neurosciences shares in Q4 2025, an estimated $72.3K.
  • Ken Griffin first reported a position in ProMIS Neurosciences in Q2 2025 and held it in 2 quarters.
  • Ken Griffin's ProMIS Neurosciences position peaked at $72.3K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.